Evidence map›Paper›PMID 36058811›Full record

ArticleUrologic oncology2022

Evaluation of post-ablation mpMRI as a predictor of residual prostate cancer after focal high intensity focused ultrasound (HIFU) ablation.

Yash S Khandwala, Shravan Morisetty, Pejman Ghanouni, Richard E Fan, Simon John Christoph Soerensen, Mirabela Rusu, Geoffrey A Sonn

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urologic oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Surveillance after Focal Therapy - a Comprehensive Review.Prostate cancer and prostatic diseases · 2025
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yash S KhandwalaDepartment of Urology, Stanford University Medical Center, Stanford, CA.
Shravan MorisettyDepartment of Urology, Stanford University Medical Center, Stanford, CA.
Pejman GhanouniDepartment of Radiology, Stanford University Medical Center, Stanford, CA.
Richard E FanDepartment of Urology, Stanford University Medical Center, Stanford, CA; Department of Radiology, Stanford University Medical Center, Stanford, CA.
Simon John Christoph SoerensenDepartment of Urology, Stanford University Medical Center, Stanford, CA.
Mirabela RusuDepartment of Radiology, Stanford University Medical Center, Stanford, CA.
Geoffrey A SonnDepartment of Urology, Stanford University Medical Center, Stanford, CA; Department of Radiology, Stanford University Medical Center, Stanford, CA. Electronic address: gsonn@stanford.edu.
Stanford Medicine · US

Funding

Rad-pathomic deep learning models to assist radiologists in differentiating aggressive from indolent prostate cancer on MRIR37CA260346 · NCI · STANFORD UNIVERSITY · PI Mirabela Rusu · 2022 to 2026
$2.8M
NCI NIH HHS R37 CA260346
6 · The paper itself

Abstract

purposeTo evaluate the performance of multiparametric magnetic resonance imaging (mpMRI) and PSA testing in follow-up after high intensity focused ultrasound (HIFU) focal therapy for localized prostate cancer.

methodsA total of 73 men with localized prostate cancer were prospectively enrolled and underwent focal HIFU followed by per-protocol PSA and mpMRI with systematic plus targeted biopsies at 12 months after treatment. We evaluated the association between post-treatment mpMRI and PSA with disease persistence on the post-ablation biopsy. We also assessed post-treatment functional and oncological outcomes.

resultsMedian age was 69 years (Interquartile Range (IQR): 66-74) and median PSA was 6.9 ng/dL (IQR: 5.3-9.9). Of 19 men with persistent GG ≥ 2 disease, 58% (11 men) had no visible lesions on MRI. In the 14 men with PIRADS 4 or 5 lesions, 7 (50%) had either no cancer or GG 1 cancer at biopsy. Men with false negative mpMRI findings had higher PSA density (0.16 vs. 0.07 ng/mL

conclusionsPersistent GG ≥ 2 cancer may occur after focal HIFU. mpMRI alone without confirmatory biopsy may be insufficient to rule out residual cancer, especially in patients with higher PSA density. Our study also validates previously published studies demonstrating preservation of urinary and sexual function after HIFU treatment.

Indexed as

Multiparametric Magnetic Resonance ImagingProstatic NeoplasmsAgedDisease ProgressionHumansMaleNeoplasm, ResidualProstateProstate-Specific AntigenProstate-Specific AntigenFocal therapyHigh intensity focused ultrasoundMagnetic resonance imagingProstate cancer

Identifiers

PMID36058811
PMCPMC10058305
OpenAlexW4294131657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.